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ABSTRACT 
The Hippo pathway controls cell proliferation, 
differentiation, and survival by regulating the 
YAP transcriptional coactivator in response to 
various stimuli, including the mechanical 
environment. The major YAP regulators are the 
LATS1/2 kinases, which phosphorylate and 
inhibit YAP. LATS1/2 are activated by 
phosphorylation on a hydrophobic motif (HM) 
outside the kinase domain by MST1/2 and other 
kinases. Phosphorylation of the HM motif then 
triggers autophosphorylation of the kinase in the 
activation loop (AL) to fully activate the kinase, 
a process facilitated by MOB1. The angiomotin 
family of proteins (AMOT, AMOTL1, and 
AMOTL2) bind LATS1/2 and promote its 
kinase activity and YAP phosphorylation 
through an unknown mechanism. Here, we show 
that angiomotins increase Hippo signaling 
through multiple mechanisms. We found that by 
binding LATS1/2, SAV1, and YAP, 
angiomotins function as a scaffold that connects 
LATS1/2 to both its activator SAV1–MST1 and 
its target YAP. Deletion of all three angiomotins 
reduced the association of LATS1 with SAV1–
MST1 and decreased MST1/2-mediated 
LATS1/2-HM phosphorylation. Angiomotin 
deletion also reduced LATS1/2’s ability to 
associate with and phosphorylate YAP. In 
addition, we found that angiomotins have an 
unexpected function along with MOB1 to 
promote autophosphorylation of LATS1/2 on the 
AL motif independent of HM phosphorylation. 
These results indicate that angiomotins enhance 
Hippo signaling by stimulating LATS1/2 
autophosphorylation and by connecting 
LATS1/2 with both its activator SAV1–MST1/2 
and its substrate YAP. 
 
Introduction 
The Hippo pathway regulates the transcriptional 
coactivators YAP and TAZ (hereafter referred to 
as YAP) to control cell fate decisions regarding 
cell proliferation, survival, and differentiation 
(1). Mis-regulation of the Hippo-YAP pathway 
is commonly associated with cancer (2). The 
LATS1 and LATS2 kinases (LATS1/2) are 
major regulators of YAP. LATS1/2 
phosphorylate YAP to trigger its cytoplasmic 
retention and degradation (3-5).  In the canonical 
Hippo pathway the MST1 and MST2 kinases 
(MST1/2) activate LATS1/2 (6). LATS1/2 can 
also be activated by MAP4K-family and TAO 
kinases (7-9). All upstream kinases 
phosphorylate LATS1/2 on a conserved 
hydrophobic motif (HM: T1079 and T1041 in 
LATS1 and LATS2 respectively). LATS1/2-HM 
phosphorylation stimulates it to 
autophosphorylate in the activation loop (AL: 
S909 and S872 in LATS1 and LATS2 
respectively) and become fully active (6,10,11). 
This process is facilitated by the MOB1 protein, 
which enhances LATS1/2-HM phosphorylation 
by MST1/2 and stimulates LATS1/2-AL 
autophosphorylation (10-12).  MST1/2 
phosphorylation of LATS1/2 is also stimulated 
by colocalization of both proteins on the 
membrane, which is promoted by SAV1 and 
NF2 respectively (13). In addition, SAV1 can 
function as a scaffold since it can bind both 
MST1/2 and LATS1/2 (14,15). Although there 
are numerous other proteins that can promote 
Hippo signaling, their mechanism of action is in 
general not well understood.  
 
A major regulator of Hippo signaling is the 
mechanical environment, which includes factors 
such as cell density, substrate stiffness, and cell 
stretch or mechanical tension. How these 
mechanical stimuli act through the core Hippo 
regulators to control YAP activity is not clear. 
Several studies have shown that the actin 
cytoskeleton, which responds dynamically to 
mechanical changes, is a major regulator of 
Hippo signaling (16-20). Reduction in F-actin 
activates LATS1/2. How F-actin controls 
LATS1/2 activity is not certain, but may involve 
angiomotins (AMOT, AMOTL1, and AMOTL2) 
(21-23). Angiomotins bind to both LATS1/2 and 
YAP, and can inhibit YAP through two 
mechanisms; 1) binding and retention of YAP in 
the cytoplasm/plasma membrane, and 2) 
activation of LATS1/2 (21,24-27). Other studies 
have shown that AMOT can control YAP 
nuclear/cytoplasmic localization, depending on 
its phosphorylation state (28). Angiomotins also 
bind the LATS1/2 activator NF2 (29,30), and a 
study using proximity-labeling found that SAV1 
and MOB1 may interact with AMOT (31). We 
and others have proposed that angiomotins may 
act as scaffolds to promote LATS1/2 activation. 
A conserved N-terminal region in the long form 
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of AMOT (AMOT130, hereafter referred to as 
AMOT) contains an F-actin binding motif, and 
flanking L/PPxY sites that bind WW-containing 
proteins (such as YAP). We have shown 
previously that F-actin and YAP compete for 
binding to angiomotins (22), which may provide 
one mechanism for how F-actin can influence 
YAP activity; when F-actin levels go down, 
angiomotins are free to bind and inhibit YAP in 
the cytoplasm and possibly activate LATS1/2. 
Angiomotins are required for relocalization of 
YAP from the nucleus to the cytoplasm when F-
actin is disrupted (22). In addition, elimination 
of angiomotin regulation of YAP causes 
patterning defects in early mouse embryos 
(26,27), transformation of MDCK cells (25), and 
epithelial to mesenchymal transition in MCF10 
cells (32). How angiomotins activate LATS1/2 
is not known. Here we show that the angiomotin 
protein AMOT interacts with multiple core 
Hippo pathway regulators to stimulate LATS1/2 
to phosphorylate YAP via three distinct 
mechanisms. First, AMOT promotes interaction 
between LATS1/2 and its activators MST1/2 
and SAV1. Second AMOT enhances LATS1/2 
phosphorylation of YAP by promoting 
interaction between the two proteins. And third, 
AMOT collaborates with MOB1 to enhance 
LATS1/2-AL autophosphorylation, even in the 
absence LATS-HM site phosphorylation.  
 
Results 
Angiomotins promote LATS1/2 activation 
Phosphorylation at the LATS2-HM site is 
presumed to be the primary regulatory site for 
LATS1/2 because, when phosphorylated, it 
promotes autophosphorylation in the activation 
loop (AL) of the kinase to make it fully active 
(6,10,11), allowing it to phosphorylate YAP and 
other substrates. We tested the effect of 
angiomotins on phosphorylation at the 
LATS1/2-HM site. Overexpression of all three 
angiomotins (AMOT, AMOTL1, and AMOTL2) 
promoted LATS2-HM phosphorylation (Figure 
1A). (Note that in this study all experiments 
utilize the long form of AMOT (AMOT130)). 
Consistent with these observations, deletion of 
all 3 angiomotin genes (Amot-3KO) in HEK293 
cells using CRISPR (Figure S1A-B) resulted in 
reduced activating phosphorylation of LATS1/2 
at the HM and AL sites after F-actin disruption 
by Latrunculin B (Lat B) treatment (Figure 1B). 
Similar results were observed in HeLa cells with 
all 3 angiomotins knocked down using siRNA 
(Figure S1C).  Consistent with our findings, 
other studies showed that knockdown of 
angiomotins reduces LATS1/2 activity, as 
judged by reduced YAP S127 phosphorylation 
in HEK293T, MDCK, and MCF10A cells 
(21,25,32). Together these findings show that 
angiomotins can activate LATS1/2 by promoting 
phosphorylation at the HM site in response to F-
actin perturbation. 
 
To better understand how angiomotins activate 
LATS1/2, we tested which core Hippo 
components are required for angiomotins to 
promote HM phosphorylation. We found that in 
HEK293 cells, MST1/2 are the primary 
LATS1/2-HM kinases since deletion of MST1/2 
(Figure S1D) causes a major decrease in HM 
phosphorylation in unperturbed, Lat B, and 
okadaic acid (OA) treated cells (Figure S1E-F). 
Consistent with this observation, the increase 
LATS2-HM phosphorylation after angiomotin 
overexpression was largely lost in MST1/2 
deleted cells (Figure 1A), suggesting that 
angiomotin stimulated LATS2-HM 
phosphorylation works primarily through 
MST1/2 in HEK293 cells. Similar results were 
observed in the absence of SAV1 and NF2 
(Figure 1C; S1D), the MST1/2 and LATS1/2 
binding partners respectively. Note that not even 
the phospho-mimetic (active) form of AMOT 
(AMOT-175E) is able to activate LATS1/2 in 
the absence of SAV1 or NF2. These results are 
consistent with the idea that angiomotins may 
act together with the two kinase modules (MST-
SAV1 and LATS1/2-NF2) to promote LATS1/2 
activation.  
 
MST1/2 and SAV1 stimulate AMOT-LATS2 
binding 
While examining how MST1/2, SAV1, and NF2 
contribute to angiomotin activation of LATS1/2, 
we discovered a potential positive feedback loop 
whereby MST1/2 and SAV1 promote AMOT-
LATS2 binding. When we tested whether 
MST1/2, SAV1, and NF2 affect AMOT-LATS2 
binding, we observed that deletion of MST1/2 or 
SAV1 greatly reduced binding of AMOT to 
LATS2 (NF2 deletion reduced binding but the 
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effect did not reach the level of significance) 
(Figure 1D-E; see S1G for further antibody 
controls). One explanation for these results 
could be that AMOT-LATS2 binding requires 
LATS2 activity, and MST1/2 and SAV1 are 
required for LATS2 activation. This would be 
consistent with our previous study showing that 
AMOTL2 bound better to wild-type than kinase 
dead LATS2, or LATS2 with both sites of 
activating phosphorylation mutated to alanine 
residues (21). We tested whether AMOT had 
similar binding preferences. This experiment 
showed that AMOT, like AMOTL2, bound 
preferentially to wild-type LATS2 compared to 
LATS2 with both sites of activating 
phosphorylation mutated (Figure 2A). Because 
LATS2 is known to phosphorylate AMOT on 
S175 (22,26,33-35), these results could be 
explained if either LATS2 phosphorylation of 
AMOT promotes AMOT-LATS2 binding, or if 
AMOT preferentially binds to the active form of 
LATS2. Consistent with the first model, we 
observed, as seen previously (26), that a 
phospho-mimetic version of AMOT (AMOT-
175E) binds to (Figure 2B) and activates LATS2 
(Figure S2A) better than the non-
phosphorylatable form of AMOT (AMOT-
175A). However, because expression of AMOT-
175E did not rescue the AMOT-LATS2 binding 
defect in MST1/2-KO cells, additional factors 
must contribute to the AMOT-LATS2 binding 
defect in MST1/2-KO cells (Figure 2C). 
Therefore, we tested the second model; namely 
that angiomotins bind preferentially to active 
LATS2. If correct, then expression of a 
phospho-mimetic version of LATS2 (LATS2-
1041E) should rescue the defect in AMOT-
LATS2 interaction in MST1/2 deleted cells. 
Indeed, this turned out to be the case (Figure 
2D). These results show that MST1/2 and SAV1 
activation of LATS1/2 stimulates a positive 
feedback mechanism by promoting AMOT-
LATS1/2 binding. 
 
AMOT is a Hippo pathway scaffold protein 
AMOT could activate LATS1/2 either by 
stimulating MST1/2 activation, or by promoting 
the ability of MST1/2 to phosphorylate 
LATS1/2. Our results support the later 
possibility since AMOT overexpression did not 
affect the levels of MST1/2 activating 
phosphorylation (Figure S2B). (Note that to 
remove potential issues with feedback from 
LATS1/2, we conducted these and subsequent 
experiments with AMOT-175E.)  We next 
investigated whether AMOT might function as a 
scaffold to bring LATS1/2 together with its 
activator MST1/2 and substrate YAP. This and 
previous studies showed that AMOT binds 
LATS1/2 (21,36). Thus one potential 
mechanism of action for AMOT could be that it 
connects LATS1/2 with the MST1/2-SAV1 
complex and YAP. Indeed, when we analyzed 
endogenous AMOT complexes using 
chromosomally tagged sfGFP-MAP-AMOT 
(37) in HEK293 cells (created using CRISPR 
mediated genome modification), we could detect 
LATS1, SAV1, MST1, and YAP coming down 
with sfGFP-MAP-AMOT isolated using 
streptavidin beads (note that part of the MAP tag 
is a streptavidin binding peptide) (Figure 3A), 
consistent with endogenous AMOT associating 
with core Hippo pathway proteins. We next 
examined whether AMOT might contribute to 
association of core Hippo pathway proteins by 
overexpressing AMOT with different 
combinations of Hippo pathway proteins 
followed by immunoprecipitation. Since AMOT 
bound LATS1/2, we tested whether AMOT 
could stimulate LATS2 activation by also 
binding MST1. While we were unable to 
observe binding between AMOT and MST1 
when both proteins were co-expressed (Figure 
3B), AMOT did bind to SAV1 in a manner that 
depended on the SAV1 WW domains and the 3 
L/PPxY motifs (WW domain ligands) in AMOT 
(Figure 3C). SAV1 expression allowed MST1 to 
come down in AMOT immune complexes 
(Figure 3B) indicating that SAV1 could bridge 
interaction between AMOT and MST1. These 
results support the notion that AMOT could 
connect LATS2 to SAV1-MST1. However, as 
previously observed in Drosophila (14), SAV1 
was also able to bind LATS2 (Figure 
3D)(presumably by interaction of its WW 
domain with the PPxY motif in LATS2), 
showing that it can act as a scaffold for MST1 
and LATS2 without AMOT (at least when over-
expressed). Interestingly, the amount of SAV1 
that came down in LATS2 immune complexes 
was enhanced by expression of AMOT (Figure 
3D). Similar experiments were also done to 
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 5 
examine how the interaction of MST1 with 
LATS2 might depend on SAV1 and AMOT 
(Figure 3E).  MST1 and LATS2 were found to 
not interact unless SAV1 was co-expressed 
(Figure 3E). As with the SAV1-LATS2 
interaction (Figure 3D), AMOT alone could not 
promote interaction between LATS2 and MST1, 
but was able to enhance the interaction of MST1 
and SAV1 with LATS2 (Figure 3E). Together 
these results suggest that AMOT may enhance 
the assembly/stabilization of a complex between 
SAV1-MST1 and LATS2. In addition, AMOT 
may also act as a scaffold to bring LATS1/2 in 
proximity with its substrate YAP. We observed 
that when YAP and LATS2 were co-expressed, 
YAP was only poorly recovered in LATS2 
immune complexes (Figure 3F) unless AMOT 
was also expressed. The ability of AMOT to 
enhance LATS2-YAP binding depended on the 
L/PPxY motifs in AMOT (Figure 3F). This 
result suggested that YAP binding by AMOT 
might not just inhibit YAP by sequestering it in 
the cytoplasm as previously reported, but might 
also bring it together with its inhibitory kinase 
LATS1/2. Consistent with this model, Amot-
3KO cells show defects in YAP phosphorylation 
(Figure S3A) and are defective in keeping YAP 
out of the nucleus after growth to high density or 
serum deprivation (Figure S3B). We also saw 
defects in association of endogenous core Hippo 
pathway proteins in the absence of angiomotins. 
Whereas immunoprecipitates of endogenous 
LATS1 from HEK293 cells contained SAV1 
and YAP, both proteins were almost completely 
absent in LATS1 immunoprecipitates from 
Amot-3KO cells (Figure 4A). Similarly, when 
we immunoprecipitated endogenous SAV1 from 
HEK293 cells, we could detect MST1, LATS1, 
AMOT, and YAP in the immune complexes. 
However SAV1 immune complexes from Amot-
3KO cells contained MST1, but almost no YAP 
and LATS1 (Figure 4B). This indicates that at 
endogenous protein levels, SAV1 alone cannot 
efficiently scaffold LATS1/2 with MST1/2. 
Collectively these results show that AMOT may 
regulate LATS1/2 and YAP at least in part by 
acting as a scaffold to connect LATS1/2 to both 
its activator SAV1-MST1/2, as well as its target 
YAP. 
 
Angiomotins promote LATS1/2-AL auto-
phosphorylation 
The ability of AMOT to promote a complex 
containing SAV1, MST1, and LATS2 could 
explain why LATS1/2 activating 
phosphorylation at the HM site (the site 
phosphorylated by MST1/2) is reduced in Amot-
3KO cells response to Lat B treatment (Figure 
1B). Similarly, we observed that LATS1/2-HM 
phosphorylation is reduced in Amot-3KO cells 
compared to wild-type when MST1 is 
overexpressed (Figure 5A). The defect in 
LATS2-HM phosphorylation in Amot-3KO cells 
in response to MST1 overexpression could be 
rescued by co-overexpression of SAV1 (Figure 
5B), consistent with SAV1 being able to replace 
the scaffolding function of angiomotins, at least 
when overexpressed. Interestingly, although 
Amot-3KO cells overexpressing MST1 and 
SAV1 had HM phosphorylation levels similar to 
wild-type controls expressing MST1 and SAV1, 
they still had a defect in LATS2 phosphorylation 
at the AL site (Figure 5B). These results raised 
the possibility that angiomotins may promote 
LATS2 autophosphorylation at the LATS2-AL 
site, independent their effect on MST1/2 
phosphorylation at the LATS2-HM site. (Note 
that the defect in LATS2-AL phosphorylation in 
Amot-3KO cells could be rescued by re-
expression of the 3 angiomotin proteins (Figure 
S1B)). To distinguish between direct effects of 
AMOT on LATS2-AL phosphorylation and 
indirect effects via LATS2-HM phosphorylation, 
we tested whether AMOT could promote AL 
phosphorylation of a version of LATS2 that 
mimicked the HM phosphorylated form 
(LATS2-1041E) but could not be regulated by 
MST1/2 (Figure S4A) or other upstream HM 
kinases. We used LATS2-1041E because we 
assumed that AMOT alone might not be able 
promote LATS2-AL phosphorylation without 
HM phosphorylation.  We found that AMOT 
expression enhanced AL phosphorylation of 
LATS2-1041E (Figure 5C). Thus, AMOT can 
promote LATS2 auto-phosphorylation at the AL 
site independent of any effects it has on LATS2-
HM phosphorylation. The only other protein 
known to stimulate LATS1/2 auto-
phosphorylation is MOB1 (10,12). We observed 
that when co-expressed (Figure S4B), MOB1A 
could be detected in AMOT immune complexes, 
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showing that the two proteins might interact. 
Therefore, we investigated the relationship 
between MOB1 and AMOT in promoting 
LATS2-AL phosphorylation. Several lines of 
evidence suggested that MOB1 may act 
independently from angiomotins and the effects 
of AMOT on LATS1/2-AL phosphorylation 
may depend on MOB1. For example, MOB1A 
binding to LATS2 was not affected by deletion 
of all three angiomotins (Figure S4C), and 
overexpression of AMOT was not able to 
significantly enhance AL phosphorylation of 
LATS2-1041E that had a point mutation in the 
MOB binding domain (R657A, named MBD) 
(11) rendering it unable to bind MOB1 (Figure 
5D). In addition, strong overexpression of 
MOB1A could stimulate similar levels of AL 
phosphorylation of LATS2-1041E in angiomotin 
deleted cells compared to wild-type cells 
(Figures 5E). Interestingly, despite having the 
same levels of LATS-AL phosphorylation the 
angiomotin deleted cells had a significant defect 
in YAP phosphorylation (Figure 5E), consistent 
with our earlier results suggesting a scaffolding 
role for angiomotins to promote LATS1/2 
phosphorylation of YAP. Other evidence 
suggests that MOB1A and AMOT may have 
additive or synergistic effects on LATS1/2-AL 
phosphorylation. When both MOB1A and 
AMOT were moderately overexpressed (at 
levels where each alone barely enhanced 
LATS2-AL phosphorylation), we observed that 
co-expression of both proteins significantly 
increased AL phosphorylation of LATS2 (Figure 
5F) beyond that observed for either protein 
alone. These results prompted us to test whether 
AMOT and MOB1A could promote AL 
phosphorylation even in the absence of HM 
phosphorylation (using LATS2-1041A). We 
found that although moderately expressed 
AMOT and MOB1A alone did not increase AL 
phosphorylation, expression of both proteins 
significantly increased AL phosphorylation of 
LATS2-1041A, albeit to lower levels than with 
wild-type LATS2 (Figure 5F). We think that the 
AL phosphorylation of LATS2-1041A was due 
to autophosphorylation and not phosphorylation 
by another kinase or endogenous LATS1/2 
because a LATS2 kinase dead mutant did not 
show AL phosphorylation after MOB1A and 
AMOT expression (Figure 5F). Together, these 
experiments indicate that AMOT and MOB1A 
can promote LATS2 autophosphorylation on the 
AL site independent of HM phosphorylation by 
upstream kinases.  
 
Discussion 
Previous studies showed that angiomotins 
promote LATS1/2 activity and YAP 
phosphorylation, but the mechanism was not 
known (21,25,32). We show here that 
angiomotins carry out these functions through 
multiple modes of action (Figure 6). Several 
lines of evidence are consistent with AMOT 
acting as a scaffolding protein. Previous studies 
have shown that angiomotins bind LATS1/2, 
NF2, and YAP (21,22,24-27,29,30), and here we 
show that they can also bind SAV1-MST1/2. 
Thus they have the ability to bring LATS1/2 
together with both their activator and substrate.  
Interestingly, the SAV1 protein has also been 
proposed to have scaffolding function because it 
binds LATS1/2 (15) and MST1 (38-41). 
However, we found that cells lacking 
angiomotins show severe defects in binding 
between endogenous SAV1-MST1 and 
LATS1/2, suggesting that at physiological levels 
angiomotins are important for SAV/MST-LATS 
complex stability. This raises the question of 
how Hippo signaling complexes are assembled 
in animals like Drosophila that lack 
angiomotins. One possible explanation is a 
rearrangement in the PPxY motif ligands for the 
SAV WW domains. In Drosophila SAV binds to 
the LATS1/2 homolog WARTS through 
interaction between its WW domains and the 5 
PPxY motifs in WARTS (14). Although similar 
mechanism could operate in humans, it may not 
be as robust because LATS1 and LATS2 contain 
fewer PPxY motifs than Drosophila WARTS 
(LATS1 and LATS2 have 2 and 1 PPxY motifs 
respectively). AMOT could act to recruit SAV1-
MST1 to AMOT-LATS2 complexes via its 3 
L/PPxY motifs (2 PPxY motifs and 1 LPxY 
motif), which could supply additional binding 
sites for the WW domains of SAV1. Thus 
Drosophila may not need angiomotins to recruit 
WW-domain proteins to WARTS because 
WARTS has 5 PPxY motifs instead of the two 
and one in LATS1 and LATS2 respectively. 
Utilization of the PPxY domains of AMOT to 
recruit WW-domain proteins to an AMOT-
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 7 
LATS1/2 complex could provide another level 
of regulation, since we have previously shown 
that the L/PPxY motifs of AMOT are masked in 
the presence of F-actin. Here we showed that the 
phospho-mimetic point mutant (AMOT-175E) 
that disrupts F-actin binding by AMOT 
(22,26,33,34) (thereby making the L/PPxY 
motifs of AMOT available for binding to WW 
domains) is better than wild-type at promoting 
LATS2-HM phosphorylation. Together this 
would create a mechanism whereby reduction in 
F-actin frees AMOT to bind the WW domains of 
both SAV1 and YAP allowing it to promote 
LATS1/2 activation and YAP phosphorylation 
by bringing LATS1/2 together with its activator 
SAV1-MST1/2 and its target YAP.  
 
This model may also be relevant to our 
observation showing weak co-
immunoprecipitation between YAP and LATS2 
except for when AMOT was co-expressed and 
reduced interaction between endogenous LATS1 
and YAP in Amot-3KO cells. Here again, 
AMOT might be acting to provide additional 
L/PPxY sites for the WW domains of YAP to 
bind. Previous reports have given differing 
results regarding interaction between LATS2 
and YAP, with some showing LATS2 interacts 
with YAP via the first WW domain of YAP (42-
44), whereas another report failed to observe co-
immunoprecipitation between YAP and LATS2 
(45). These studies could be consistent with the 
interaction between YAP and LATS2 being 
weak, but observable if high enough levels of 
each protein are expressed. We previously 
showed that a competition for binding to AMOT 
between F-actin and YAP caused reduction in F-
actin levels trigger AMOT to bind YAP and 
sequester it in the cytoplasm (22). Our current 
results suggest that the increased binding of 
AMOT to YAP caused by reduction in F-actin 
levels may help connect LATS1/2-AMOT 
complexes to YAP to promote its 
phosphorylation and cytoplasmic sequestration. 
 
The other major discovery of this study was that 
AMOT can stimulate LATS2 to 
autophosphorylate on its activation loop. 
Previously MOB1 was the only protein known 
to enhance LATS1/2-AL phosphorylation 
(10,12). We observed that co-expression of 
AMOT with MOB1A greatly enhanced LATS2-
AL phosphorylation more than expression of 
either protein alone. Because both AMOT and 
MOB1A promote LATS1/2-HM site 
phosphorylation and this phosphorylation can 
trigger LATS1/2 to autophosphorylate at the AL 
site, we needed to be able to analyze LATS2-AL 
phosphorylation in isolation. To do this we used 
LATS2 mutants that had the HM 
phosphorylation site mutated to either non-
phosphorylatable alanine or to phospho-mimetic 
glutamate. These results showed that activation 
or increased levels of AMOT and MOB1 can 
activate LATS2 even without activation by 
upstream kinases. The physiological relevance is 
at this point not clear. It is possible that AMOT 
and MOB1 always act in conjunction with 
LATS1/2-HM phosphorylation to promote 
activation of LATS1/2 through AL 
phosphorylation, or alternatively they might 
function under some circumstances to activate 
LATS2 independent of HM phosphorylation. 
Further studies will be required to address these 
possibilities. 
 
Experimental Procedures 
Cell culture and drug and siRNA treatments 
HEK 293 were grown in Dulbecco’s modified 
Eagle medium (DMEM, GIBCO) supplemented 
with 10% (v/v) fetal bovine serum (FBS, 
GIBCO) and 1% (v/v) penicillin/streptomycin 
(GIBCO) in a humidified incubator at 37°C with 
5% CO2. Cells were incubated with Latrunculin 
B (Lat B) for 45 minutes at concentrations of 1 
uM (ENZO LIFE SCIENCES) or 0.2 uM 
(SIGMA). Okadaic acid (OA) was used at 100 
uM for 2 hours. Angiomotins were stabilized 
with XAV-939 (Selleckchem) overnight at 
10uM. Knockdowns with siRNA in Hela cells 
were performed using 75 nM of control (GL2) 
siRNA or 25 nM each of AMOT, AMOTL1, and 
AMOTL2 SMARTpool siRNA (Dharmacon M-
015417,M-017595, and  M-013232, 
respectively), and 18 ul of Lipofectamine 
RNAiMAX (Invitrogen) in 6 well plates 
following the manufacturer directions. After 48 
hours cells were collected following Latrunculin 
B treatment as indicated. 
 
Plasmids and mutagenesis 
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The term “well” below refers to a single well 
from a 12-well plate. AMOT (wt, S175E, and 
S175A (22)), AMOTL1, and AMOTL2 were 
expressed from pCDNA4-Myc-His at 400 ng per 
well for all assays except the experiments in 
Supplemental Figure S2A, where 750 ng were 
used. In Supplemental Figure S1B all three 
Angiomotins where expressed together from 
500ng of plasmid per 10cm plate. SAV1 was 
expressed from pcDNA3-3HA, LATS2 (wt and 
phospho-mimetic LATS2-T1041E (21)) from 
pcDNA3.1-FLAG, MST1 from pcDNA-HA, all 
at 400 ng per well. MOB1A was expressed from 
pcDNA3.1-Myc at 400 ng per well and pEGFP 
at 200ng per well. AMOT-3PxY-Myc was 
described in (22). The LATS2-R657A MOB1 
binding site mutant (MBD) was made on the 
1041E background, using the QuickChange II 
Site mutagenesis kit (Agilent) and primers 
designed using the manufacturer’s web tool 
(CTACCAGAAAGAGTCTAATTACAACGCG
TTAAAGAGGGCCAAGATG and 
CATCTTGGCCCTCTTTAACGCGTTGTAAT
TAGACTCTTTCTGGTAG, 
http://www.genomics.agilent.com/primerDesign
Program.jsp). A similar procedure was followed 
to make SAV1-ww, but using QuickChange 
Lightning Multi (Agilent), and primers 
AACACAAATACAACTCACGCGAGCCATG
CTCTTGAGCGAGAAGGAC (for ww1), and 
CACAAATAAGAAGGCCCAAGCCAGGCAT
GCCTGTGCTCCTAGTGTA (for ww2).  
 
Antibodies 
The following dilutions were used for antibodies 
in Western blots. The mouse anti- MST1 
(Proteintech, 66663) was used at 1:2000. The 
mouse anti-tubulin (Proteintech, 66031), mouse 
anti-FLAG (Sigma, F3165), mouse anti-GFP 
(Santa Cruz, 9996), rabbit anti-Myc (Santa Cruz, 
789), and mouse anti-Myc (Santa Cruz, 40) were 
used at 1:1000. The rabbit anti YAP 
(Proteintech, 13584), rabbit anti pYAP S127 
(Cell Signaling, 4911), rabbit anti LATS1 (Cell 
Signaling, 3477), rabbit anti LATS2 (Cell 
Signaling, 5888), rabbit anti pLATS1-S909 
(Cell Signaling, 9157), rabbit anti MST1/2 
(Bethyl, A300-466A), and rabbit anti pLATS1-
T1079 (Cell Signaling, 8654) were used at 
1:500. The mouse anti-SAV1 (Santa Cruz, 
374366) and mouse anti YAP (Santa Cruz, 
101199) were used at 1:100. The rabbit anti-
AMOT antibody was generated by Maria 
Fernandes (Université Laval, CHUQ-CHUL 
Research Centre) and used at 1:2000. The rabbit 
anti AMOTL1 was provided by Anthony 
Schmitt (The Pennsylvania State University) and 
used at 1:1000. The rabbit anti AMOTL2 was 
generated by Wenqi Wang (University of 
California Irvine) and used at 1:1000. 
Immunoprecipitation of endogenous proteins 
was carried out with rabbit anti-SAV1 (Cell 
Signaling, 13301) and rabbit anti LATS1 (Cell 
Signaling, 3477) 
 
Cell transfection, immunoprecipitation, and 
Western blotting 
For the experiment in Supplemental Figure S1B, 
AMOT, AMOTL1, and AMOTL2, were 
transfected at low levels into HEK293 Amot-
3KO cells with FuGENE® HD (Promega), 
according to manufacturer’s protocol. Rescued 
A3KO cells were trypsinized 8 hours post 
transfection, re-plated, and incubated overnight. 
The next morning, cells were treated with Lat B 
as indicated. Lipofectamine 2000 (Invitrogen) 
was the transfection reagent of choice for all 
other experiments. Since the Hippo pathway gets 
activated by cell resuspension, all protein was 
collected from cells snap frozen with liquid 
nitrogen in the plates they were grown on. For 
experiments in Figures 3A, and 4A-B, a lysis 
buffer containing glycerol was used (10% 
glycerol, 20 uM Tris HCl pH 7, 137 mM NaCl, 
2 mM EDTA, 1% NP40). The lysis buffer for all 
other experiments contained 1% NP-40, 150 
mM NaCl, 2 mM EDTA, 6 mM Na2HPO4, and 
4 mM NaH2 PO4. Both lysis buffers contained 
phosphatase and protease inhibitors (1mM 
PMSF, 1mM Na3VO4, and mammalian protease 
inhibitor cocktail (Sigma)) was added to frozen 
cells and a cells were solubilized with the help 
of a cell scraper and back and forth pipetting. 
Lysates were cleared by centrifugation at 15,000 
g for 5 min at 4°C. Dynabeads (Invitrogen) were 
used for all immunoprecipitation experiments 
according to the manufacturer’s protocol. Non-
specific IgG antibodies were typically used as a 
control for immunoprecipitation experiments. 
For experiments involving 
coimmunoprecipitation of proteins with different 
epitope tags, control experiments were done to 
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show that antibodies against the tag on the 
protein being immunoprecipitated did not bind 
to the co-expressed protein being tested for co-
immunoprecipitation (Supplemental Figure 
S1G). 
 
CRISPR mediated KO cell line development  
Target sequences were selected using the web 
tool developed by the Zhang lab at M.I.T. 
(http://crispr.mit.edu/). Complementary oligos 
(below) containing the target sequence 
(uppercase) and appropriate overhangs 
(lowercase) were annealed and cloned into a 
variant of the px330 plasmid with puromycin 
resistance (46). AMOT: 
caccGCCATACACCAGCAAGCCAC and 
aaacGTGGCTTGCTGGTGTATGGC, 
AMOTL1: 
caccgCAAGTTCATGTTCTCGGTTG and 
aaacCAACCGAGAACATGAACTTGc, 
AMOTL2: 
caccGCAGCGTGCGCGTCTCAGTC and 
aaacGACTGAGACGCGCACGCTGC, MST1: 
caccGGATCGTTATGGAGTACTGT and 
aaacACAGTACTCCATAACGATCC, MST2: 
caccGTTATGGAGTACTGTGGCGC and 
aaacGCGCCACAGTACTCCATAAC, SAV1: 
caccGTTGGAATTGTTGGACCATGc and 
aaacGCATGGTCCAACAATTCCAAc, NF2: 
caccgGAACTCCATCTCGGCGTCCA and 
aaacTGGACGCCGAGATGGAGTTC. KO cell 
lines were generated by transfecting 500 ng of 
the px330-based plasmid containing the 
CRISPR target sequence into HEK293 cells 
plated in 12-well plates using Lipofectamine 
2000 (Invitrogen). The next day, cells were 
placed under selection for 48 hours with 1 µg/ml 
of Puromycin (GIBCO). Puromycin resistant 
cells were then heavily diluted and plated on 10 
cm plates for colony isolation. Clonal lines were 
then expanded, and the expression of the target 
gene was determined by Western blot. Clonal 
lines that lacked expression of the target gene 
were re-isolated again from single cells and 
tested by Western blot to ensure clonality. The 
sfGFP-MAP-AMOT expressing cells were 
created similarly to the KO cell lines except that 
instead of px330, we used MLM3636 (Addgene 
#43860) to generate the sgRNA (guide sequence 
acaccGAATTTCTCATCTCTATTGCg and 
aaaacGCAATAGAGATGAGAAATTCc) that 
cuts near the start codon for AMOT), JDS246 
(Addgene # 43861) to express Cas9, and a 
rescue plasmid containing sfGFP-MAP flanked 
by ~700 base pairs of genomic sequence 
immediately upstream and downstream of the 
AMOT start codon. 
Pooled puromycin resistant cells were used for 
further analysis. Western blotting using AMOT 
and GFP antibodies was used to confirm that the 
cells expressed full length sfGFP-MAP-AMOT. 
 
Quantification and Statistical Analysis 
Students t-test analysis (*P ≤ 0.05, ** P ≤ 0.01, 
*** P ≤ 0.001, **** P ≤ 0.0001) were 
performed with the Graphpad web tool 
(https://www.graphpad.com/quickcalcs/ttest1.cf
m) and represent mean ± SD for experiments 
done in triplicates. Western blot densitometry 
quantifications were either performed by LI-
COR Odyssey (when fluorescent probes were 
used), or by ImageJ (47) on images obtained 
with a Bio-Rad Chemi-Touch, when HRP 
conjugated antibodies were used. 
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Figure Legends 
Figure 1. Angiomotins require MST1/2, SAV1, and NF2 to activate LATS1/2. A) HEK293 (wt) or 
HEK293 cells with MST1 and MST2 inactivated using CRISPR (MST1/2-KO) were transfected with a 
LATS2-FLAG expressing plasmid and either a control plasmid, or a plasmid for expressing Myc-tagged 
versions of each of the 3 angiomotin genes (AMOT, AMOTL1, AMOTL2). Cell lysates were analyzed by 
western blotting using antibodies against the LATS1/2-HM phosphorylation site (pLATS2-HM), Myc 
(Angiomotins-Myc), FLAG (LATS2-FLAG). Tubulin levels in cell lysates are also shown. B) HEK293 
(wt) or HEK293 cells with AMOT, AMOTL1 and AMOTL2 inactivated using CRISPR (Amot-3KO) 
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were treated with or without Latrunculin B (Lat B) and cell lysates were analyzed by western blotting 
using antibodies against LATS1/2-HM phosphorylation, LATS1/2-AL phosphorylation, and LATS1. 
Tubulin levels in cell lysates are also shown. Quantification of LATS1/2-HM and LATS1/2-AL 
phosphorylation relative to untreated wt HEK293 cells are shown. (Mean ± SD; n=3; NS=P≥0.05, 
*P≤0.05, **P≤0.01, T-test). C) HEK293 (wt) or HEK293 cells with NF2 (NF2-KO) or SAV1 (SAV1-
KO) inactivated using CRISPR were transfected with a control plasmid, or a plasmid for expressing Myc-
tagged versions of AMOT, or the AMOT-S175E mutant. Cell lysates were analyzed by western blotting 
using antibodies against the LATS1/2-HM phosphorylation site (pLATS1/2-HM) and Myc (AMOT-
Myc). Tubulin levels in cell lysates are also shown. D) HEK293 (wt) or MST1/2-KO HEK293 cells were 
transfected with LATS2-FLAG and AMOT-Myc expressing plasmids. Myc or control (IgG) antibodies 
were used for immunoprecipitations from cell lysates, and immune complexes and cell lysates were 
analyzed by western blotting for LATS2-FLAG and AMOT-Myc levels. Quantification of LATS2 levels 
in AMOT immune complexes is shown. (Mean ± SD; n=3; ***P≤0.001, T-test).  E) HEK293 (wt), NF2-
KO, or SAV1-KO HEK293 cells were transfected with LATS2-FLAG and AMOT-Myc expressing 
plasmids. Myc or control (IgG) antibodies were used for immunoprecipitations from cell lysates, and 
immune complexes and cell lysates were analyzed by western blotting for LATS2-FLAG and AMOT-
Myc levels. Quantification of LATS2 levels in AMOT immune complexes is shown. (Mean ± SD; n=3; 
**P≤0.01, NS=P≥0.05, T-test). 
 
Figure 2. AMOT binds to active forms of LATS2. A) HEK293 cells were transfected with plasmids for 
expressing AMOT-Myc and either LATS2 or LATS2 with the AL and HM phosphorylation sites (S872 
and T1041) mutated to alanine (LATS2-2A). Myc or control (IgG) antibodies were used for 
immunoprecipitations from cell lysates, and immune complexes and cell lysates were analyzed by 
western blotting for LATS2-FLAG and AMOT-Myc levels. Quantification of AMOT levels in LATS2 
immune complexes is shown. (Mean ± SD; n=3; **P≤0.01, T-test). B) HEK293 cells were transfected 
with plasmids for expressing LATS2-FLAG and either AMOT-Myc, AMOT-175A-Myc, or AMOT-
175E-Myc. Immunoprecipitations were performed on each cell lysate with either FLAG (LATS2-FLAG) 
or control (IgG) antibodies, and immune complexes and cell lysates were analyzed by western blotting for 
LATS2-FLAG and AMOT-Myc levels. Quantification of AMOT levels in LATS2 immune complexes is 
shown. (Mean ± SD; n=3; **P≤0.01, ***P≤0.001, T-test). C) HEK293 cells (wt) or MST1/2-KO cells 
were transfected with plasmids for expressing LATS2-FLAG and AMOT-175E-Myc. 
Immunoprecipitations were performed on each cell lysate with either FLAG (LATS2-FLAG) or control 
(IgG) antibodies, and immune complexes and cell lysates were analyzed by western blotting for LATS2-
FLAG and AMOT-Myc levels. Quantification of AMOT levels in LATS2 immune complexes is shown. 
(Mean ± SD; n=3; ***P≤0.001, T-test). D) HEK293 cells (wt) or MST1/2-KO cells were transfected with 
plasmids for expressing LATS2-T1041E-FLAG and AMOT-Myc. Immunoprecipitations were performed 
cell lysates with either Myc (AMOT-Myc) or control (IgG) antibodies, and immune complexes and cell 
lysates were analyzed by western blotting for LATS2-FLAG and AMOT-Myc levels. Quantification of 
LATS2 levels in AMOT immune complexes is shown. (Mean ± SD; n=3; NS=P≥0.05, T-test) 
 
Figure 3. AMOT promotes assembly of LATS2-SAV1-MST1 complexes. A) HEK293 cells expressing 
sfGFP-AMOT from the chromosomal locus were created using CRISPR mediated genome modification 
(see Experimental Procedures). Streptavidin beads were used to pull down (PD) sfGFP-MAP-AMOT 
protein (GFP-AMOT) (Wild-type HEK293 cells (wt) where the endogenous AMOT locus has not been 
tagged with the sfGFP-MAP tag were used as a control). Protein complexes on beads were analyzed by 
western blotting using antibodies against the indicated proteins. The levels of these proteins in cell lysates 
is shown. B) HEK293 cells were transfected with plasmids for expressing HA-MST1, HA-SAV1 and 
AMOT-Myc as indicated. Immunoprecipitations were performed cell lysates with either Myc (AMOT-
Myc) or control (IgG) antibodies, and immune complexes and cell lysates were analyzed by western 
blotting for HA-MST1, HA-SAV1, and AMOT-Myc levels. C) HEK293 cells were transfected with 
plasmids for expressing HA-SAV1 or HA-SAV1 with both WW domains mutated (HA-SAV1-2ww) and 
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either AMOT-Myc or AMOT-3PxY-Myc (eliminates all 3 L/PPxY motifs in AMOT). 
Immunoprecipitations were performed on each cell lysate with either Myc (AMOT-Myc) or control (IgG) 
antibodies, and immune complexes and cell lysates were analyzed by western blotting for HA-SAV1 and 
AMOT-Myc levels. D) HEK293 cells were transfected with plasmids for expressing HA-SAV1, LATS2-
FLAG, and AMOT-Myc as indicated. Immunoprecipitations were performed on each cell lysate with 
either FLAG (LATS2-FLAG) or control (IgG) antibodies, and immune complexes and cell lysates were 
analyzed by western blotting for LATS2-FLAG, HA-SAV1, and AMOT-Myc levels. Quantification of 
SAV/LATS2 ratios in LATS2 immune complexes for cells expressing LATS2 and SAV1 (LATS2+S) or 
LATS2, SAV1, and AMOT (LATS2+A+S) is shown. (Mean ± SD; n=3; *P≤0.05, T-test). E) HEK293 
cells were transfected with combinations of plasmids for expressing LATS2-FLAG, HA-MST1, HA-
SAV1, and AMOT-Myc as indicated. Immunoprecipitations were performed on each cell lysate with 
either FLAG (LATS2-FLAG) or control (IgG) antibodies, and immune complexes and cell lysates were 
analyzed by western blotting for LATS2-FLAG, HA-MST1, HA-SAV1, and AMOT-Myc levels. 
Quantification of MST1/LATS2 and SAV1/LATS2 ratios in LATS2 immune complexes for cells co-
expressing LATS2 and MST1 (L + M), LATS2, MST1 and SAV (L + M + S), LATS2, MST1 and 
AMOT (L + M + A), and LATS2, MST1, AMOT and SAV1 (L + M + A + S)is shown. (Mean ± SD; 
n=3; *P≤0.05, **P≤0.01, ****P≤0.0001 T-test). F) HEK293 cells were transfected with combinations of 
plasmids for expressing GFP-LATS2, FLAG-YAP2, and AMOT-Myc as indicated. Immunoprecipitations 
were performed on each cell lysate with either GFP (LATS2-GFP) or control (IgG) antibodies, and 
immune complexes and cell lysates were analyzed by western blotting for LATS2-GFP, FLAG-YAP2, 
and AMOT-Myc levels.  
 
Figure 4. Angiomotins function as scaffolds for the Hippo pathway in vivo. A) HEK293 (wt) and 
Amot-3KO HEK293 cells were grown to high density and serum starved for 4 hours. 
Immunoprecipitations were performed on cell lysates with either anti-LATS1 or control (IgG) antibodies, 
and immune complexes and cell lysates were analyzed by western blotting for AMOT, SAV1, LATS1, 
and YAP levels. (LATS1 bg: residual LATS1 signal after stripping). B) HEK293 (wt) and Amot-3KO 
HEK293 cells were grown as in (A). Immunoprecipitations were performed on cell lysates with either 
anti-SAV1 or control (IgG) antibodies, and immune complexes and cell lysates were analyzed by western 
blotting for AMOT, MST1, SAV1, LATS1, and YAP levels.  
 
Figure 5. AMOT promotes LATS2-AL activation loop phosphorylation independent of LATS2-HM 
phosphorylation. A) HEK293 (wt) or Amot-3KO HEK293 cells were transfected with a control plasmid, 
or a plasmid for expressing HA-MST1. Cell lysates were analyzed by western blotting using antibodies 
against the LATS1/2-HM phosphorylation site (pLATS1/2-HM), HA (HA-MST1), and LATS1. Tubulin 
levels in cell lysates are also shown. Quantification of LATS1/2-HM phosphorylation is shown. (Mean ± 
SD; n=3; NS=P≥0.05, *P≤0.05, **P≤0.01, ****P≤0.0001, T-test). B) HEK293 (wt) or Amot-3KO KO 
HEK293 cells were transfected with a control plasmid, or a combination of plasmids (L + M + S) for 
expressing LATS2-FLAG, HA-MST1, and HA-SAV1. Cell lysates were analyzed by western blotting 
using antibodies for LATS2-HM and LATS2-AL phosphorylation, FLAG (LATS2-FLAG), and HA (HA-
MST1 and HA-SAV1). Tubulin levels in cell lysates are also shown. Quantification of LATS1/2-HM 
phosphorylation is shown. (Mean ± SD; n=3; NS=P≥0.05, **P≤0.001, T-test).  C) HEK293 cells were 
transfected with a control plasmid, LATS2-1041E-FLAG, AMOT-175E-Myc as indicated. Cell lysates 
were analyzed by western blotting using antibodies for LATS2-AL phosphorylation (pLATS2-AL), 
FLAG (LATS2-1041E-FLAG), and Myc (AMOT-175E-Myc). Tubulin levels in cell lysates are also 
shown. Quantification of LATS1/2-AL phosphorylation relative to LATS2-1041E is shown. L-1041E: 
LATS2-1041E, A-175E: AMOT-175E. (Mean ± SD; n=3; ****P≤0.0001, T-test). D) HEK293 cells were 
transfected with a control plasmid, or LATS2-1041E-FLAG, LATS2-1041E-MBD-FLAG (MBD is a 
LATS2 mutant defective for binding MOB1), AMOT-175E-Myc as indicated. Cell lysates were analyzed 
by western blotting using antibodies for LATS2-AL phosphorylation (pLATS2-AL), FLAG (LATS2-
1041E-FLAG or LATS2-1041E-MBD-FLAG), and Myc (AMOT-Myc). Tubulin levels in cell lysates are 
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also shown. Quantification of LATS1/2-AL phosphorylation relative to LATS2-1041E-FLAG levels is 
shown. L-1041E: LATS2-1041E, A: AMOT-175E. (Mean ± SD; n=3; NS=P≥0.05, **P≤0.01, T-test). E) 
HEK293 (wt) or Amot-3KO HEK293 cells were transfected with a plasmid for expressing LATS2-
1041E-FLAG and either a control plasmid or a plasmid for expressing Myc-MOB1A. Cell lysates were 
analyzed by western blotting using antibodies for LATS2-AL phosphorylation (pLATS2-AL), YAP 
phosphorylation on S127 (pYAP-S127), FLAG (LATS2-1041E-FLAG), and Myc (Myc-MOB1A). 
Tubulin levels in cell lysates are also shown. Quantification of LATS1/2-AL and pYAP-S127 
phosphorylation is shown. (Mean ± SD; n=3; NS=P≥0.05, *P≤0.05, **P≤0.01, ***P≤0.001, 
****P≤0.0001, T-test). F) HEK293 cells were transfected with a control plasmid, LATS2-FLAG, 
LATS2-1041E-FLAG, kinase dead LATS2 (LATS2-KD-FLAG), AMOT-Myc, or Myc-MOB1A as 
indicated. Cell lysates were analyzed by western blotting using antibodies for LATS2-AL 
phosphorylation (pLATS2-AL), FLAG (LATS2-FLAG), Myc (AMOT-Myc and Myc-MOB1A). Tubulin 
levels in cell lysates are also shown. L: LATS2, L-1041A: LATS2-1041A, L-KD: LATS2-kinase dead, 
A: AMOT-175E, M: MOB1A. Quantification of LATS1/2-AL phosphorylation is shown. (Mean ± SD; 
n=3; NS=P≥0.05, *P≤0.05, **P≤0.01, ****P≤0.0001, T-test).  
 
Figure 6. Model for AMOT function in Hippo signaling. (A) When F-actin levels are high AMOT is 
bound to F-actin and poorly interacts with its binding partners. (B) If F-actin levels are reduced, AMOT 
becomes phosphorylated by LATS and is free to bind YAP, SAV-MST, and LATS. Assembly of this 
complex allows MST to phosphorylate LATS on the HM site. Both AMOT phosphorylation and LATS 
HM phosphorylation enhance AMOT-LATS binding. (C) To become fully active LATS must 
autophosphorylate on the AL site. HM phosphorylation enhances LATS autophosphorylation. In addition, 
we show that both MOB1 and AMOT enhance LATS-AL phosphorylation independent of any effects 
they have on HM phosphorylation. (D) The ability of fully active LATS to phosphorylate YAP may be 
enhanced by formation of a LATS-AMOT-YAP complex. Note that the model is speculative and its 
purpose is illustrate the primary steps involved in AMOT activation of Hippo signaling. The Hippo 
pathway is regulated at many other levels, which could be occurring at the same time but are not shown 
for simplicity.  It is not presently clear whether complexes exist in cells as pictured with all components 
simultaneously bound to each other. 
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 published online September 28, 2018J. Biol. Chem. 
  
 10.1074/jbc.RA118.004187Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on N
ovem
ber 15, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
